ViaCyte raises $80 million for diabetes therapy

Diabetes therapy developer ViaCyte has raised $80 million, its largest financing to date, ?the San Diego biomedical company said Wednesday.

ViaCyte will use the money to advance its stem cell-derived therapies, said Paul Laikind, president and CEO of the privately held company. ViaCyte is combining…